Bioequivalence of a Low Strength Fixed Dose Combination Tablet of Empagliflozin/Linagliptin/Metformin Extended Release Compared to the Free Combination of Empagliflozin, Linagliptin, and Metformin Extended Release Tablets Following Oral Administration in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Study)
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2018
At a glance
- Drugs Empagliflozin/linagliptin/metformin (Primary) ; Empagliflozin; Linagliptin; Metformin
- Indications Diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 06 Nov 2018 Status changed from active, no longer recruiting to completed.
- 25 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 03 Sep 2018 Status changed from not yet recruiting to recruiting.